Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.
Biomarker and diagnostic research for rubella has been reported in the published literature.
7 clinical trials registered, 2 recruiting. Interventions under study include other interventions and biologic therapy. Pipeline includes 3 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07406360](https://clinicaltrials.gov/study/NCT07406360) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:52 AM UTC
Genetic and Rare Diseases Info Center
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
PHASE3 |
GlaxoSmithKline |
RECRUITING |
[NCT06667206](https://clinicaltrials.gov/study/NCT06667206) | Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings | PHASE2 | University of Oxford | UNKNOWN |
[NCT07112846](https://clinicaltrials.gov/study/NCT07112846) | Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections | — | Hospital Israelita Albert Einstein | NOT_YET_RECRUITING |
[NCT06815835](https://clinicaltrials.gov/study/NCT06815835) | Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months | PHASE3 | International Centre for Diarrhoeal Disease Research, Bangladesh | NOT_YET_RECRUITING |
[NCT07338851](https://clinicaltrials.gov/study/NCT07338851) | the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines | — | China National Biotec Group Company Limited | NOT_YET_RECRUITING |
383 publications have been identified in PubMed for rubella. Kisho has analyzed 91 by research type. Research spans Epidemiology / Natural History (38%), Review / Meta-Analysis (30%), and Clinical Trial Publication (10%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 35 | 38% |
Research summaries | 27 | 30% |
Clinical study results | 9 | 10% |
Patient case studies | 6 | 7% |
Other research | 5 | 5% |
Laboratory research | 5 | 5% |
Testing and diagnosis research | 4 | 4% |
Carvajal R (2026). [PMID: 42160053](https://pubmed.ncbi.nlm.nih.gov/42160053/). *JAMA Netw Open*. [Clinical Trial Publication]
Shrestha B (2026). [PMID: 41731408](https://pubmed.ncbi.nlm.nih.gov/41731408/). *BMC Infect Dis*. [Epidemiology / Natural History]
Shukla S (2026). [PMID: 29939656](https://pubmed.ncbi.nlm.nih.gov/29939656/). *Unknown Journal*. [Case Report / Case Series]
Mahmood R (2026). [PMID: 32809680](https://pubmed.ncbi.nlm.nih.gov/32809680/). *Unknown Journal*. [Epidemiology / Natural History]
Teklu MW (2026). [PMID: 41555289](https://pubmed.ncbi.nlm.nih.gov/41555289/). *BMC Public Health*. [Epidemiology / Natural History]
Gailani AE (2026). [PMID: 40938300](https://pubmed.ncbi.nlm.nih.gov/40938300/). *J Hosp Med*. [Review / Meta-Analysis]
De Melo LC (2025). [PMID: 40507747](https://pubmed.ncbi.nlm.nih.gov/40507747/). *J Clin Med*. [Review / Meta-Analysis]
Lebo E (2025). [PMID: 40402850](https://pubmed.ncbi.nlm.nih.gov/40402850/). *MMWR Morb Mortal Wkly Rep*. [Epidemiology / Natural History]
Oh JK (2025). [PMID: 40736849](https://pubmed.ncbi.nlm.nih.gov/40736849/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Sayi TS (2025). [PMID: 40179934](https://pubmed.ncbi.nlm.nih.gov/40179934/). *Lancet Child Adolesc Health*. [Clinical Trial Publication]
AI-curated news mentioning rubella
Updated Mar 5, 2026
A report from Florida highlights cases of congenital rubella syndrome, emphasizing the need for increased awareness and vaccination efforts. The findings aim to inform public health strategies to prevent further cases.